��ɫ��

��ɫ��

Donate To Research Join The AAN

Events

Resources For

Abstract Details

Title A Phase 1b Clinical Trial with Tolerogenic Dendritic Cells for Multiple Sclerosis and Neuromyelitis Óptica

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 159

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Irati Zubizarreta PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Albert Saiz (Hospital Clinico De Barcelona)	Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janseen. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for novartis. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
	No disclosure on file